AMGN — Amgen Inc.

Amgen Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue Growth: Amgen reported a 10% increase in sales for 2025, with total revenues reaching approximately $36 billion.
• Blockbuster Products: 14 products achieved over $1 billion in sales, and 13 products experienced double-digit growth.
• Earnings: Non-GAAP earnings per share (EPS) for the full year were strong, contributing to double-digit growth in both revenues and EPS.
• Operating Margin: Non-GAAP operating margin was reported at 46%.
• Free Cash Flow: Generated $8.1 billion in free cash flow.
• R&D Investment: Non-GAAP R&D spending increased by 22% year-over-year to $7.2 billion.

2. Strategic Updates and Business Highlights

• Product Performance: Key growth drivers included Repatha (36% growth), Evenity (34% growth), and TestSpire (52% growth). The rare disease portfolio grew 14% to nearly $5.2 billion.
• Regulatory Approvals: Notable approvals included Eplizna for generalized myasthenia gravis and Aplisna for IgG4-related disease.
• Oncology Advances: Imdeltra received full FDA approval for small cell lung cancer, becoming a standard of care.
• Biosimilars: The biosimilars portfolio generated $3 billion in sales, with significant contributions from products like PAV Blue.

3. Forward Guidance and Outlook

• 2026 Revenue Projections: Expected total revenues between $37 billion to $38.4 billion, driven by continued strength in key growth products.
• EPS Guidance: Non-GAAP EPS anticipated between $21.6 to $23.
• R&D Spending: Projected to grow low single digits, excluding business development costs.
• Seasonal Headwinds: Anticipated lower mid-single-digit growth in Q1 due to insurance changes and inventory build-up.

4. Bad News, Challenges, or Points of Concern

• Competition: Increased competition from biosimilars, particularly for products like Prolia and Otezla, which are expected to see sales erosion.
• Regulatory Challenges: The FDA requested a voluntary withdrawal of Tavneos, raising concerns about the drug's future.
• Market Dynamics: Potential impacts from new oral PCSK9 inhibitors on Repatha's market share, although Amgen remains confident in Repatha's unique data package.
• First Quarter Sales: Expected to be the lowest of the year due to typical seasonal trends and increased competition.

5. Notable Q&A Insights

• Meritide's Market Position: Amgen is optimistic about Meritide's potential in obesity and diabetes, emphasizing its unique dosing schedule and efficacy.
• Aplisna's Uptake: Initial uptake of Aplisna for generalized myasthenia gravis is promising, with a significant portion of patients being bio-naive.
• Repatha's Strategy: Amgen plans to leverage new data from the Vesalius trial to enhance Repatha's positioning in both primary and secondary prevention markets.
• Challenges in Sjogren's Syndrome: The complexity of drug development in Sjogren's syndrome was acknowledged, with confidence in the ongoing Phase III trials for dasodilumab.

Overall, Amgen's Q4 2025 earnings call highlighted strong financial performance and strategic growth initiatives, while also addressing competitive pressures and regulatory challenges that could impact future results.